FDA Accepts MyMD Pharmaceuticals' Investigational New Drug Application (IND) for Phase 2 Study of oral TNF-α inhibitor MYMD-1® in Rheumatoid Arthritis (RA) | Region
BALTIMORE--(BUSINESS WIRE)--Aug 14, 2023--
Source: eagletribune.com
Page 2 - Robert Schatz News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Robert Schatz. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Robert Schatz Today - Breaking & Trending Today
MyMD Pharmaceuticals, Inc.: MyMD Pharmaceuticals to Present Data on Oral TNF-a Inhibitor MYMD-1 at the British Society for Immunology (BSI) Congress 2022
- Preclinical and early clinical studies of MYMD-1, an oral, small-molecule, selective TNF-a inhibitor, suggest future potential to disrupt the Rheumatoid Arthritis market - MyMD Pharmaceuticals
Source: finanznachrichten.de
Free heart health webinars to be offered by Northwest Health
Northwest Health will be offering free heart health webinars via its Facebook page.
Source: 5newsonline.com